ABIT:XETRA:XETRA-AXA IM ACT Biodiversity Equity UCITS ETF - USD Acc EUR (EUR)

ETF | Others |

Last Closing

USD 11.552

Change

0.00 (0.00)%

Market Cap

USD 0.41B

Volume

366.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.31 (+0.60%)

USD 577.24B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.51%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.17 (+0.61%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.17 (+0.60%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.02 (+0.06%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.04%)

USD 112.46B
8R80:XETRA Amundi Index Solutions - Amund..

+0.42 (+0.28%)

USD 112.09B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.29 (+0.56%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+0.86 (+0.16%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.13 (+0.55%)

USD 79.79B

ETFs Containing ABIT:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.94% 64% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.94% 63% D 64% D
Trailing 12 Months  
Capital Gain 15.53% 59% D- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.53% 59% D- 60% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.11% 54% F 53% F
Dividend Return 5.11% 53% F 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.39% 69% C- 76% C+
Risk Adjusted Return 69.13% 77% C+ 79% B-
Market Capitalization 0.41B 63% D 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike